Big Bets and Breakouts: Surf Air Soars on Palantir Bet, GRNY ETF Outperforms, AMD Eyes AI Gains
Market-Moving Event Alerts
Remember to move the mail to the Primary inbox if this mail is in other inboxes.
Hi All! This week, StockNews.AI identified and published 114 successful event alerts across multiple sectors — with nearly 20% of them capturing price movements exceeding an impressive 10%.
*Data Captured Between 7/7 00:00am - 7/11 12:00 pm EDT.
*Penny stocks are excluded from the 10%+ price change analysis.
Top 3 AI Events you can’t miss for today, 7/11.
Forbes
BullishLongTermSRFMCorporate Developments
What's Driving Surf Air Mobility Stock's 2x Surge?
- Palantir increased its stake in Surf Air to 20%, boosting investor confidence.
- Surf Air plans to electrify short-haul air travel by 2027, enhancing growth potential.
- Revenue grew 31.2% but profitability remains a key concern for Surf Air.
- $91 million debt leads to high Debt-to-Equity Ratio of 30% for Surf Air.
- Current P/S ratio of 2.7x is competitive against the S&P 500's 3.1x.
CNBC
VeryBullishLongTermGRNYIndustry News
Tom Lee's Granny Shots ETF is crushing the market and raking in cash
- GRNY reached $1.5 billion AUM in just eight months after launch.
- The fund outperformed MSCI USA Large Cap Index, returning 13.7% since inception.
- Performance ranks in the top three percent of nearly 1,400 funds this year.
- Investors are making regular purchases, indicating strong ongoing interest in GRNY.
- Thematic stock selection provides a disciplined process to maximize consistent results.
Investopedia
BullishShortTermAMDIndustry News
AMD Stock Popped After Analyst Said New AI Chips Could Take On Nvidia's—Watch These Key Price Levels
- AMD's stock rose after AI chip comparisons with Nvidia.
- The stock broke out of a flag pattern with high trading volume.
- Overhead resistance levels identified at $175 and $215.
- AMD's MI350 chips are competitive with Nvidia's offerings.
- Shares are up 86% from April but lag behind Nvidia's performance.
Here’re the top 5 most-surged stocks captured by our AI Event signal this week.
*Penny stocks are not included in the list.
GlobeNewsWire
BullishLongTerm 646.08%PROKEarnings
ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes
- REGEN-007 results show significant kidney function improvement in Group 1.
- 78% reduction in eGFR decline was statistically significant (p<0.001).
- Safety profile of rilparencel remains consistent with previous studies.
- FDA Type B meeting planned to confirm eGFR slope as a surrogate endpoint.
- ProKidney targets accelerated approval for rilparencel to address CKD market.
Business Wire
BullishLongTerm 90.68%LGPSShares Buyback
LogProstyle Inc. Announces Approval of Share Repurchase Program by the Board of Directors
- LogProstyle announced a share repurchase program for $543,455.
- Program includes repurchase of up to 1,086,910 common shares.
- Acquisitions are set from July 1, 2025, to June 30, 2026.
- The program aims to enhance shareholder value through disciplined capital allocation.
- LGPS commits to innovative and sustainable lifestyle projects.
GlobeNewsWire
BearishShortTerm -37.79%RXSTEarnings
RxSight, Inc. Announces Preliminary Second Quarter 2025 Revenue and Revised 2025 Guidance
- RxSight expects Q2 2025 revenue of $33.6M, down 4% YoY.
- LAL sales fell 1%; LDD sales dropped 45% Q/Q.
- 2025 revenue guidance reduced to $120M-$130M from $160M-$175M.
- Gross margin guidance increased to 72%-74%; operating expenses raised.
- CEO emphasizes customer support for better outcomes and adoption.
GlobeNewsWire
BullishLongTerm 35.66%RYTMM&A
Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity
- Bivamelagon achieved significant BMI reductions of -9.3% and -7.7%.
- Post-hoc analysis shows bivamelagon's effectiveness comparable to setmelanotide.
- Patients reported a mean reduction of -2.8 points in hunger scores.
- Rhythm plans to request FDA meeting for Phase 3 trial in obesity.
- Company will present findings at The Endocrine Society’s Annual Meeting.
GlobeNewsWire
BullishLongTerm 31.4%COGTEarnings
Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis
- Bezuclastinib shows significant symptom score improvement in NonAdvSM patients.
- 87.4% of treated patients had over 50% reduction in serum tryptase.
- NDA submission for bezuclastinib to FDA expected by end of 2025.
- Cogent maintains a strong financial position with $237 million cash.
- Top-line results from related trials PEAK and APEX expected in late 2025.
CNBC
VerybullishShortTerm 30.63%KLGM&A
Cereal maker WK Kellogg shares jump 50% on report of possible $3 billion deal with Ferrero
- WK Kellogg shares jumped over 50% on acquisition news.
- Ferrero may finalize a $3 billion purchase of WK Kellogg soon.
- Kellanova separated from WK Kellogg in 2023 amidst market shifts.
- Consumer preferences are shifting towards healthier breakfast options.
- The deal signifies increasing consolidation in the packaged food sector.
Want to see customized event news?
Subscribe and Activate Event Alert Today!
Disclaimer: The content provided in this Email should be used for informational purposes only and in no way should be relied upon for financial advice.
Reply